Clinical Trial

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
Trial Details
NCT Number NCT06277024
Lead Sponsor Fujian Medical University
Conditions Overall Response Rate
Enrollment 50 participants
Start Date 2023-01-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-26